Eli Lilly CEO: One-Third of New GLP-1 Pill Users Choose Foundayo
Eli Lilly's CEO told CNBC that a third of new GLP-1 pill patients are taking Foundayo as the company accelerates production to compete with Novo Nordisk.
Eli Lilly is gaining ground in the oral GLP-1 drug market, with the company's chief executive revealing that approximately one-third of new patients starting a GLP-1 pill are choosing Foundayo, the drugmaker's entry in the fast-growing weight-loss and diabetes treatment category.
The CEO made the disclosure in an interview with CNBC, signaling that Lilly's oral option is carving out meaningful market share despite entering the space after rival Novo Nordisk, which established an early lead with its own GLP-1 pill offering.
Read more Eli Lilly CEO: 700,000 Seniors Begin GLP-1s Under Medicare Coverage →
Lilly is actively ramping up manufacturing capacity to meet demand, a move that reflects both the competitive pressure from Novo and the broader surge in patient and physician interest in non-injectable GLP-1 therapies. The oral format is widely seen as a potential expansion of the overall GLP-1 market by reaching patients who are reluctant to use injectable treatments.
The GLP-1 drug class has reshaped the pharmaceutical landscape in recent years, driven by strong clinical evidence supporting weight loss and cardiovascular benefits. Competition between Lilly and Novo Nordisk in both injectable and pill formats has intensified as both companies race to secure prescriptions and manufacturing scale.
Analysts have viewed the oral GLP-1 segment as a key battleground for long-term market leadership, and Lilly's early uptake figures for Foundayo suggest the company is mounting a credible challenge to Novo's head start. Continue reading at Business News.
